Innate Pharma SA vs Moderna, Inc.
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
In short
- Moderna, Inc. is the larger company by market value: $90.1 B against $230 M for Innate Pharma SA, 392 times as much (market caps of Jan 5, 2024 for Innate Pharma SA and Oct 30, 2026 for Moderna, Inc.). Innate Pharma SA's value is the last on file, from Jan 5, 2024: no market-data feed is connected for its exchange yet.
- Moderna, Inc. had more revenue: $1.9 B against $10 M for Innate Pharma SA, both in the year to December 2025.
- Both made a net loss: $55 M for Innate Pharma SA and $2.8 B for Moderna, Inc.
- Moderna, Inc. keeps more of each dollar of sales: a net margin of -145.2% against -545.9% for Innate Pharma SA.
- Moderna, Inc. employs more people: 4,700 against 181 at Innate Pharma SA. Each employee brings in about $56,133 of revenue at Innate Pharma SA and $413,617 at Moderna, Inc.
- Moderna, Inc.'s revenue grew faster in its latest fiscal year: -39.9% against -53.3% for Innate Pharma SA.
Market value, the same start = 100
From Jan 2020: how each one's value moved, whatever its size.
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | Innate Pharma SA IPHYF | Moderna, Inc. MRNA · #275 in the world |
|---|---|---|
| Profile | ||
| Country | 🇫🇷 France | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Founded | — | 2010 |
| Size | ||
| Market cap | $230 M* | $90.1 B |
| Revenue | $10 M | $1.9 B |
| Net income | $-55 M▲ best | $-2.8 B |
| Employees | 181 | 4,700 |
| Valuation | ||
| Price to sales | — | 35.7× |
| Price to book | — | 10.4× |
| Free cash flow yield | — | -2.3% |
| Profitability | ||
| Gross margin | — | 55.4% |
| Operating margin | -599.5% | -158.1%▲ best |
| Net margin | -545.9% | -145.2%▲ best |
| Return on equity | — | -28.9% |
| Growth | ||
| Revenue growth | -53.3% | -39.9%▲ best |
| Revenue growth, 3 years a year | -44.9%▲ best | -53.4% |
| Financial strength | ||
| Debt to equity | — | 0.1× |
| Cash | ||
| Free cash flow margin | -587.2% | -106.2%▲ best |
| Shareholder returns | ||
| Shareholder yield | — | 0.0% |
| Strength scores | ||
| Piotroski F-score | — | 3 of 9 |
| Altman Z-score zone | — | safe |
| Data as of | Market cap Jan 2024; ratios FY2025 | Market cap Oct 2026; ratios FY2025 |
Questions and answers#
Which is bigger, Innate Pharma SA or Moderna, Inc.?
Moderna, Inc. is the larger company by market value: $90.1 B against $230 M for Innate Pharma SA, 392 times as much (market caps of Jan 5, 2024 for Innate Pharma SA and Oct 30, 2026 for Moderna, Inc.). Innate Pharma SA's value is the last on file, from Jan 5, 2024: no market-data feed is connected for its exchange yet.
Which makes more money, Innate Pharma SA or Moderna, Inc.?
Moderna, Inc. had more revenue: $1.9 B against $10 M for Innate Pharma SA, both in the year to December 2025. Both made a net loss: $55 M for Innate Pharma SA and $2.8 B for Moderna, Inc.
Which is more profitable, Innate Pharma SA or Moderna, Inc.?
Moderna, Inc. keeps more of each dollar of sales: a net margin of -145.2% against -545.9% for Innate Pharma SA.
Which has more employees, Innate Pharma SA or Moderna, Inc.?
Moderna, Inc. employs more people: 4,700 against 181 at Innate Pharma SA. Each employee brings in about $56,133 of revenue at Innate Pharma SA and $413,617 at Moderna, Inc.
Which is growing faster, Innate Pharma SA or Moderna, Inc.?
Moderna, Inc.'s revenue grew faster in its latest fiscal year: -39.9% against -53.3% for Innate Pharma SA.